TREATMENT OF RESISTANT DEPRESSIONS AND CASE OF SUCCESSFUL USE OF DONEPEZIL HCl IN THEIR THERAPY
Background. In this article some approaches how to treat a stadium of resistant depression are described. There is also a description of the successful use of inhibitors acetylholinesterase donepezil hydrochloride (Aricept) in treatment of this kind of depression. Taking into account a great number of depressive patients who are resistant to usual antidepressivs these new approaches to treatment are of a great importance due to the fact that in many cases previous treatments of a depressive patients proved to be unsuccessful. This article is considered to be one of the first description in respect of the use of inhibitors of acetylcholinesterase in treatment of resistant depressions.
Conclusions. In case of resistant depressions, one of the possibilities of its treatment is the use of inhibitors of acetylcholinesterase (and may be others) in combination with antidepressants.
Young AH. Recurrent unipolar depression requires prolonged treatment. The British Journal of Psychiatry 2001; 178: 294–5.
Stahl MS. Depression and bipolar disorders. In: Stahl MS ed. Essential psychopharmacology. 2nded. Cambridge: Cambridge University Press, 2000: 136–44.
Paykel ES. Epidemiology of refractory depression. In: Nolen WS, Zohar J, Roose SP eds. Refractory depression. Chichester-New York-Brisbane-Toronto-Singapore: Wiley, 1995: 3–19.
Terzič D. Medikamentozno zdravljenje rezistentnih depresij. In: Romih J, Žmitek A eds. Zdravljenje z antidepresivi. Begunje: Medium d.o.o., 1997: 167–80.
Windler S, Sasson Y, Cohen R, Zohar J. The role of oestrogen augmentation in females with refractory depression. In: Nolen WS, Zohar J, Roose SP eds. Refractory depression. New York-Brisbane-Toronto-Singapore: Wiley, 1995: 155–7.
Fürst-Koren T. Rezistentna depresija. Viceversa 2000; 34–6.
Demytenaere K, Ganse van E, Gregorie J, Gaens E, Mesters P. Compliance in depressed patients treated with fluoxetine or amitriptiline. Int Cl Psychopharmacology 1998; 13: 11–7.
Rogers SL, Friedhof LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46: Suppl 1: 1–6.
Rogers SL, Cooper NM, Suhovaty R, Pederssen JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46: Suppl 1: 7–12.
Kemmerich M, Quartz P, Berger FM, Küthman A. Donepezil in therapy of refractory depression. The Journal of the European College of Neuropsychopharmacology 2000; 10: Suppl 3: 264–4.
Sket D. Patofiziološke osnove antidepresivnega zdravljenja. In: Romih J, Žmitek A eds. Zdravljenje z antidepresivi. Begunje: Medium d.o.o., 1997: 30–56.
Pepeu G. Preclinical pharmacology of cholinesterase inhibitors. In: Giacobini E ed. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000: 145–53.
Artigas F. New data on augmentation strategies in depression. The Journal of the European College of Neuropsychopharmacology 2000; 10: Suppl 3: 203–3.
Palazidou E. Pharmacological management of depression with anxiety. London: Mosby-Wolfe medical communications, 2000: 1–24.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.